Anti-Tumour Necrosis Factor-alpha Therapy in Crohn’s Disease: Clinical and Health Economic Aspects
Keywords:
MedicineReferences
1. Blam ME, Stein RB, Lichtenstein GR. Integrating anti-tumor necrosis factor therapy in inflammatory bowel disease: current and future perspectives. Amer J Gastroenterol 2001; 96(7):1977-97.
2. Tooson JD, Varilek GW. Inflammatory diseases of the colon. Narrowing a wide field of symptoms and possible causes. Postgrad Med 1995 Nov;98(5):46-8, 54, 57-8 passim.
3. Cohen RD, Larson LR, Roth JM, et al. The cost of hospitalization in Crohn’s disease. Am J Gastroenterol 2000; 95(2):524-30.
4. Cohen RD, Papalia P, Hanauer SB. Infliximab as steroid sparing agent in luminal Crohn’s disease. University of Chicago, Chicago, IL.
5. Oxford IBD Study (unpublished data).
6. Hay AR, Hay JW. Inflammatory bowel disease: medical cost algorithms. J Clin Gastroenterol 1992; 14(4):318-27.
7. Hay AR, Hay JW. Inflammatory bowel disease: costs-of-illness. J Clin Gastroenterol 1992; 14(4):309-17.
2. Tooson JD, Varilek GW. Inflammatory diseases of the colon. Narrowing a wide field of symptoms and possible causes. Postgrad Med 1995 Nov;98(5):46-8, 54, 57-8 passim.
3. Cohen RD, Larson LR, Roth JM, et al. The cost of hospitalization in Crohn’s disease. Am J Gastroenterol 2000; 95(2):524-30.
4. Cohen RD, Papalia P, Hanauer SB. Infliximab as steroid sparing agent in luminal Crohn’s disease. University of Chicago, Chicago, IL.
5. Oxford IBD Study (unpublished data).
6. Hay AR, Hay JW. Inflammatory bowel disease: medical cost algorithms. J Clin Gastroenterol 1992; 14(4):318-27.
7. Hay AR, Hay JW. Inflammatory bowel disease: costs-of-illness. J Clin Gastroenterol 1992; 14(4):309-17.
Downloads
Published
2002-01-01
How to Cite
McGuire, F. (2002). Anti-Tumour Necrosis Factor-alpha Therapy in Crohn’s Disease: Clinical and Health Economic Aspects. Trinity Student Medical Journal , 3(1), Page 49–53. Retrieved from https://ojs.tchpc.tcd.ie/index.php/tsmj/article/view/1916
Issue
Section
Reviews
License
Authors retain copyright and grant the journal the right of first publication with the work simultaneously licensed under a Creative Commons Attribution (CC-BY) 4.0 License that allows others to share the work with an acknowledgement of the work’s authorship and initial publication in this journal.
Provided they are the owners of the copyright to their work, authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal’s published version of the work (e.g., post it to an institutional repository, in a journal or publish it in a book), with an acknowledgement of its initial publication in this journal.
